Clinical Trials in IBD

This program will include a discussion of off-label treatment and investigational agents not approved by the FDA for use in the United States.

Evolving Treatment Landscape in IBD

Conventional Treatments for UC and CD

FDA-Approved Biologics for UC and CD

UC Treatment Pathway

Conventional and Evolving Treatment Strategies for CD

Limitations of Current Biologic Treatments for IBD

Unmet Therapy Needs in IBD

Importance of Randomized, Controlled Trials

Challenges in the Current IBD Clinical Trial Environment

Evolution of Outcomes Measures in IBD Trials

Select Investigational Therapies for UC and CD IL Inhibitors

Select Investigational Therapies for UC and CD Other Classes

Patient Barriers to Participating in IBD Trials

Patient Barriers to Participating in IBD Trials Patient Survey Results

Physician Barriers

Referring Patients to IBD Trials

Participating in an IBD Trial as an Investigator

Recruiting and Retaining Patients on Study

Novel Trial Designs in IBD

Summary and Concluding Remarks

Abbreviations